Goldberg RM. Which strategies will lead to progress in the management of colorectal cancer? Gastrointest Caner Res 2007; 1(4 Suppl 2):S33–6.Google Scholar
Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998;4:2039–45.PubMedGoogle Scholar
Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst 2002;94:1883–8.PubMedCrossrefGoogle Scholar
McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043–8.PubMedCrossrefGoogle Scholar
de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 2005;44:147–73.PubMedCrossrefGoogle Scholar
Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105.PubMedCrossrefGoogle Scholar
Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther 2018. doi: .CrossrefWeb of SciencePubMedGoogle Scholar
Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist 2012;17:296–302.Web of ScienceCrossrefPubMedGoogle Scholar
Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2099–105.Web of ScienceCrossrefPubMedGoogle Scholar
Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 2012;11:263–7.CrossrefPubMedWeb of ScienceGoogle Scholar
Freeman K, Saunders MP, Uthman OA, Taylor-Phillips S, Connock M, Court R, et al. Is monitoring of plasma 5-fluorouracil levels in metastatic/advanced colorectal cancer clinically effective? A systematic review. BMC Cancer 2016;16:523.CrossrefWeb of ScienceGoogle Scholar
Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit 2009;31:688–94.CrossrefPubMedWeb of ScienceGoogle Scholar
Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T, et al. Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin Colorectal Cancer 2016;15:381–8.PubMedCrossrefWeb of ScienceGoogle Scholar
About the article
Published Online: 2019-01-30
Published in Print: 2019-06-26
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Ralf-Dieter Hofheinz: Consulting fee: Saladax.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.